Nabi Biopharmaceuticals (NABI)

Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

On March 4, 2005, the Audit Committee of our Board of Directors concluded that our previously issued financial statements for the fiscal years ended December 27, 2003 and December 28, 2002, should no longer be relied upon. We will restate our previously issued financial statements for 2003 and 2002 in our Annual Report on Form 10-K for the fiscal year ended December 25, 2004. The Audit Committee of our Board of Directors has discussed the matters disclosed in this report with Ernst & Young LLP, our independent registered public accounting firm.

We will restate our previously issued financial statements to reflect a modification in our accounting for amortization expense for our intangible asset related to our right to manufacture our vaccine against S. aureus infections, StaphVAX^® at Dow Biopharmaceuticals Contract Manufacturing (“Dow”). The asset was fully written off in 2003 when we terminated our agreement with Dow. This restatement has no impact on our balance sheet at December 27, 2003 or our cash position and our financial results previously furnished on our Form 8-K dated February 15, 2005 for the year ended December 25, 2004 or our guidance for future periods.

During the process of finalizing the 2004 financial statements, we determined that we had received a benefit from our intangible manufacturing right asset in prior fiscal years when we had recorded no amortization expense. This determination led to our decision to restate the financial statements for these periods for additional amortization expense. The following table summarizes the impact of this restatement on the company’s results of operations for the following periods:

Net (loss) income originally reported as $(6.8) million or $(0.16) per share for the year ended December 27, 2003 and $2.1 million or $0.05 per share for the year ended December 28, 2002 have been restated as $(6.1) million or $(0.14) per share and $1.5 million or $0.04 per share, respectively.

In October 2003 we made a decision to establish a new manufacturing relationship with Cambrex Bio Science Baltimore, Inc. to support an opportunity for earlier commercialization of StaphVAX in Europe. As a result, we terminated our contract manufacturing agreement with Dow on October 9, 2003 and reported a non-cash write off equal to the recorded value of the manufacturing right asset as of that date. As restated, this write off amount totals $9.7 million versus $12.6 million reported previously. The restatement of amortization expense related to this asset will not require restatement of our December 27, 2003 balance sheet.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.